BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $108 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.66 -3.1%
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 1
Rating Summary:
25 Buy, 10 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 10 | New: 1
Join SI Premium – FREE
Stifel analyst Paul Matteis lowered the price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $108.00 (from $118.00) while maintaining a Buy rating.
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $94 at Oppenheimer
- Teva Pharma (TEVA) PT Raised to $48 at BofA Securities
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $66 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
